Supplemental material
Future Oncology
Volume 19, 2023 - Issue 36
Systematic Review
Real-World Outcomes for First Line Next-Generation Hormonal Agents in Metastatic Prostate Cancer: A Systematic Review
Robert Hettle1 Payer Simulation & Analytics,
Oncology Market Access and Pricing,
AstraZeneca,
Cambridge,Cambridgeshire,CB2 8PA,UKCorrespondence[email protected]
https://orcid.org/0000-0002-1100-1266
https://orcid.org/0000-0002-1100-1266, Adela Mihai2 Health Economics & Payer Evidence,
Oncology Market Access and Pricing,
AstraZeneca,
Cambridge,Cambridgeshire,CB2 8PA,UKhttps://orcid.org/0000-0003-2033-8394
https://orcid.org/0000-0003-2033-8394, Shona H Lang3 Mtech Access,
York,North Yorkshire,YO10 5NY,UKhttps://orcid.org/0000-0002-4883-8393
https://orcid.org/0000-0002-4883-8393, Sophie Tatman3 Mtech Access,
York,North Yorkshire,YO10 5NY,UKhttps://orcid.org/0000-0002-8692-5447
https://orcid.org/0000-0002-8692-5447 & Stephanie L Swift3 Mtech Access,
York,North Yorkshire,YO10 5NY,UKhttps://orcid.org/0000-0002-8545-8322
https://orcid.org/0000-0002-8545-8322